Astellas Beats Challenges To Blockbuster Cancer Patent
Pharmaceutical giant Astellas persuaded a London court on Tuesday to spare vital patent protections for its blockbuster prostate cancer therapeutic Xtandi, rebuffing a series of challenges attempting to clear the way...To view the full article, register now.
Already a subscriber? Click here to view full article